Millennium Management
ANRO icon

Millennium Management’s Alto Neuroscience ANRO Stock Holding History

Millennium Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,300
Closed -$370K – 6547
2024
Q3 		$370K Buy
+32,300
New +$395K ﹤0.01% 5058

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Millennium Management's ANRO Position: Q1 2026 in Review

Millennium Management increased its Alto Neuroscience (ANRO) stake by 30% in Q1 2026, buying an estimated $3.56M and bringing the position to 821,982 shares worth $18.5M. The position accounts for 0.01% of the portfolio, ranked #1619.

Millennium Management first reported a position in ANRO in Q1 2024 and has held it in 7 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Millennium Management held 821,982 shares of Alto Neuroscience worth $18.5M as of Q1 2026.
  • Millennium Management bought 191,997 Alto Neuroscience shares in Q1 2026, an estimated $3.56M.
  • Alto Neuroscience made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1619 holding.
  • Millennium Management first reported a position in Alto Neuroscience in Q1 2024 and has held it in 7 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.